Halogenated sulfidohydroboranes for nuclear medicine and boron neutron capture therapy
US5653957A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 1, 1996 |
| Grant date | Aug 5, 1997 |
| Priority date | — |
| Expiry date | Nov 1, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K41/0095
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for performing boron neutron capture therapy for the treatment of tumors is disclosed. The method includes administering to a patient an iodinated sulfidohydroborane, a boron-10-containing compound. The site of the tumor is localized. by visualizing the increased concentration of the iodine labelled compound at the tumor. The targeted tumor is then irradiated with a beam of neutrons having an energy distribution effective for neutron capture. Destruction of the tumor occurs due to high LET particle irradiation of the tissue secondary to the incident neutrons being captured by the boron-10 nuclei. Iodinated sulfidohydroboranes are disclosed which are especially suitable for the method of the invention. In a preferred embodiment, a compound having the formula Na.sub.4 B.sub.12 I.sub.11 SSB.sub.12 I.sub.11, or another pharmaceutically acceptable salt of the compound, may be administered to a cancer patient for boron neutron capture therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.